Brief: Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement With Debiopharm For Lunresertib
15/07/2025 21:43
July 15 (Reuters) - Repare Therapeutics Inc RPTX.O: REPARE THERAPEUTICS ENTERS EXCLUSIVE WORLDWIDE LICENSING AGREEMENT WITH DEBIOPHARM FOR LUNRESERTIB REPARE THERAPEUTICS INC - TO RECEIVE $10 MILLION UPFRONT, $257 MILLION IN MILESTONES REPARE THERAPEUTICS INC - DEBIOPHARM TO SPONSOR MYTHIC STUDY AND DEVELOP LUNRESERTIB Source text: ID:nBw7rPgMna Further company coverage: RPTX.O
Recent news on Repare Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Repare Therapeutics Announces Acquisition Of Polθ ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration
Brief: Repare Signs Support Agreements With Key Shareholders For Xenotherapeutics Deal
Repare Therapeutics Q2 net loss narrows to $16.7 mln